Podcasts about Pharmacogenomics

Text the show! The Lindsay Clancy trial reignited America's argument over postpartum mental health and access to psychiatric care.Chad thinks we're arguing about the wrong thing.During cross-examination, Clancy's psychiatrist was questioned about testing she did not use—including pharmacogenomic, or PGx, testing. That testimony raises a much larger question: What happens after a patient gets access to mental health care?Because access and quality are not the same thing.In this Monologue Monday episode of Common Sense with Chad Law, Chad breaks down the Clancy testimony, the national debate over postpartum psychiatric treatment, what PGx testing can reveal about medication metabolism, the evidence for and against its wider adoption, and why current professional guidance leaves him asking one deceptively simple question:If PGx shouldn't be used routinely, when SHOULD it be used?Chad also shares his own experience with severe clinical depression, nearly two decades of psychiatric medications, and the genetic testing that transformed his understanding of his own treatment. This isn't an episode about declaring Lindsay Clancy guilty or innocent.It's about whether America has spent so long demanding more mental health care that we've neglected to ask whether Americans are receiving better mental health care.

Multiomics: The Next Frontier In Precision Medicine And Diagnostics Standard blood tests aren't giving you the most accurate picture of your health. Our expert examines the critical blind spots in standard medical testing and reveals emerging technology that catches disease at the cellular level. Guest: Dr. Adrijana Kekic, CEO & founder, Futurome Host and Producer: Kristen Farrah   Closing The Info Gap: A New App That's Empowering Patients And Caregivers Patients routinely forget up to 80 percent of the information shared during a doctor's appointment. Thankfully, a new app puts control directly back into the hands of patients by bridging this critical information gap and eliminating the stress of lost instructions. Our expert explores how empowering individuals with clear, accessible records of their care can transform the patient experience and relieve burnout for healthcare providers. Guests: Dr. Arpan Parikh, psychiatrist, CEO & co-founder, Kin Health Host: Greg Johnson Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiomics: The Next Frontier In Precision Medicine And Diagnostics Standard blood tests aren't giving you the most accurate picture of your health. Our expert examines the critical blind spots in standard medical testing and reveals emerging technology that catches disease at the cellular level. Guest: Dr. Adrijana Kekic, CEO & founder, Futurome Host and Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Broadcast from KSQD, Santa Cruz on 7-09-2026: Researchers refined a technique to reverse skin cell aging by about 30 years while preserving cellular identity. Exposing adult fibroblasts to Yamanaka factors—stopping before full reversion to pluripotent stem cells,reset the epigenetic clock and gene expression patterns to resemble much younger cells. The rejuvenated fibroblasts produced significantly more collagen, migrated faster to close artificial wounds, and showed reversal of gene expression patterns associated with Alzheimer's and cataracts. Since long-term epidemiologic data doesn't yet exist, Dr. Dawn follows up on last week's vaping question by exploring cancer mechanisms. Vaping aerosols impair DNA repair fidelity while triggering IL-6, IL-8, and TNF-alpha secretion. Nicotine-derived nitrosamines, reactive carbonyls (formaldehyde, acetaldehyde, acrolein) are generated when propylene glycol and vegetable glycerin are heated. Upregulated cytochrome P450 enzymes convert precarcinogens like benzopyrene into carcinogens. Mice exposed for 54 weeks developed lung adenocarcinomas in 22% and precancerous bladder hyperplasia in 57%, with markers matching those show predict lung cancer years before diagnosis. The Mexican Biobank—which includes over 40,000 samples from all 31 Mexican states revealed dramatic regional variation in drug-metabolism genes driven by Indigenous ancestry. In Chiapas, nearly 40% of the population carries two copies of a CYP2D6 variant reducing fentanyl metabolism, versus just 10% in Sinaloa. The SLCO1B1 variant hindering statin metabolism is found in over 15% of Yucatán residents., where 8 million Mexicans take statins. Dr. Dawn discusses both the promise and potential dark side of population genetic testing, including UK plans to genotype all children at birth for inborn errors of metabolism. Dr. Dawn briefly revisits the recent Indian study showing conch-shell blowing reduces sleep apnea by 34%, comparing it to earlier didgeridoo research, both of which strengthen airway muscles through forced-blowing exercises. A caller from Capitola recovering from non-Hodgkin's lymphoma near the L5 nerve asks about Japanese Kampo medicine formulas (Goshajinkigan, Yokukansan) for post-treatment nerve pain. Dr. Dawn suggests the pain likely originates from scar tissue tethering the nerve, and recommends consulting the Oriental Medicine Doctor program at Five Branches in Santa Cruz where faculty can advise on herbal formulas that trace back thousands of years through cultural exchange between China and Japan. Dr. Dawn explains Lp(a):lipoprotein(a), a small protein string attached to LDL particles that promotes clumping and clotting, is a genetically-determined coronary artery disease and stroke risk factor invisible to standard lipid panels. Levels of 250 particles double coronary risk and 350 particles triple it. Less than 75 is normal. Two new pharmaceutical strategies are in development to reduce Lp(a) : antisense oligonucleotides (single-stranded RNA that recruits RNase H to cleave target mRNA) and small interfering RNA (double-stranded RNA that triggers destruction of matching mRNA). Pelacarsen, a monthly injection in Phase 3 trials, reduces Lp(a) by 80%. These gene-silencing platforms open therapeutic possibilities for previously undruggable orphan diseases. Vitamin K2 is produced in the gut microbiome. MK-4 is most common in humans. Dr. Dawn recommends MK7 for stabilizing coronary calcium plaques and directing calcium into bone. A study of hepatitis B and C patients found MK4 to be protective in hepatocellular carcinoma. HCC developed in 2 of 21 MK-4-treated patients versus 9 of 19 controls, with a risk ratio of 0.2. MK-4 activates protein kinase A in vitro, inhibits HCC invasiveness, and restores apoptosis signaling that cancer cells normally block. Dr. Dawn recommends a couple milligrams of MK-4 daily for anyone with cirrhosis or prior hepatitis B or C infection.

A study of rapamycin in Niemann-Pick C raises an important question: what if the success of a treatment depends on a patient's wider genetic background? Dr Andrés Klein discusses pharmacogenomics, modifier genes and why precision medicine may need to go far beyond making the diagnosis. A Rapamycin Pharmacogenomic Approach for the Childhood Dementia Niemann-Pick C Benjamín Szenfeld, et al https://doi.org/10.1002/jimd.70214

In this episode, Michel Mommejat, President of A.D.A.M. Innovations, shares how genomics and AI are transforming healthcare from reactive treatment to preventative wellcare. Recorded in Tokyo, this conversation explores what your DNA can reveal as a biological blueprint, why Japan serves as the world's laboratory for healthy aging, and how combining genetic data with biomarkers and lifestyle information creates a dynamic, personalized health ecosystem. Michel also discusses the ethical frameworks needed to protect the most sensitive data that exists, the concept of Artificial General Gene Intelligence, and practical applications like pharmacogenomics that are already changing how we think about medication. Tune in for a visionary conversation on the future of health and longevity.

Dr. Houda Hachad, Vice President of Clinical Operations at Aranscia, highlights the importance of regular medication reviews in an age of growing polypharmacy and advancements in the use of pharmacogenomics to identify potential risks. The key goal is to use the minimal effective dose of a medication and determine which drugs are most effective for treating identified conditions without causing unintended side effects. Adopting a preemptive pharmacogenomic testing approach for patients taking more than 5 drugs is noted as a way to reduce hospital readmissions, emergency room visits, and adverse drug events. Houda explains, "So polypharmacy is becoming more and more common. I think the data shows that up to 40% of adults now take a lot of medications. And polypharmacy is typically defined as the regular use of five medications or more. But in some settings, we're seeing what we call excessive polypharmacy, which is using nine or more." "So there are multiple patient cohorts, as you can imagine, that take these medications, definitely patients in hospital settings, older patients, patients that suffer from behavioral health issues, and any chronic conditions, patients with diabetes, hypertension, and obesity are going to be your typical polypharmacy patients. So our tools, which span genetic testing, medication reviews, and the use of various patient information to provide precision care, allow us to simplify and help doctors mitigate the risks associated with polypharmacy."   "Each time you add a medication to a patient, you're increasing the risk of having these adverse drug events. We have tools that can reduce the risk of polypharmacy, including pharmacogenomics." #Aranscia #Polypharmacy, #DrugGeneInteractions #dpydTesting #MedicationSafety #Pharmacogenomics  aranscia.com Download the transcript here

Dr. Houda Hachad, Vice President of Clinical Operations at Aranscia, highlights the importance of regular medication reviews in an age of growing polypharmacy and advancements in the use of pharmacogenomics to identify potential risks. The key goal is to use the minimal effective dose of a medication and determine which drugs are most effective for treating identified conditions without causing unintended side effects. Adopting a preemptive pharmacogenomic testing approach for patients taking more than 5 drugs is noted as a way to reduce hospital readmissions, emergency room visits, and adverse drug events. Houda explains, "So polypharmacy is becoming more and more common. I think the data shows that up to 40% of adults now take a lot of medications. And polypharmacy is typically defined as the regular use of five medications or more. But in some settings, we're seeing what we call excessive polypharmacy, which is using nine or more." "So there are multiple patient cohorts, as you can imagine, that take these medications, definitely patients in hospital settings, older patients, patients that suffer from behavioral health issues, and any chronic conditions, patients with diabetes, hypertension, and obesity are going to be your typical polypharmacy patients. So our tools, which span genetic testing, medication reviews, and the use of various patient information to provide precision care, allow us to simplify and help doctors mitigate the risks associated with polypharmacy."   "Each time you add a medication to a patient, you're increasing the risk of having these adverse drug events. We have tools that can reduce the risk of polypharmacy, including pharmacogenomics." #Aranscia #Polypharmacy, #DrugGeneInteractions #dpydTesting #MedicationSafety #Pharmacogenomics  aranscia.com Listen to the podcast here

On episode 109 of Astonishing Healthcare, host Justin Venneri explores pharmacogenomics (PGx) with a trio of experts: Caitlin Munro, PharmD (Clinical Partnerships Lead, Judi Health); Haleh Campbell, PharmD (Clinical Programs Administration Manager, Judi Health); and Houda Hachad, PharmD (Vice President of Clinical Operations, Aranscia). Together, they break down what PGx is, why now is the right moment for broader adoption, and how genetics can shape the way each of us processes and responds to medications.The conversation moves from the basics to the practical: where the evidence is strongest, which patients stand to benefit most, and what it takes to apply PGx in a way that's clinically responsible and genuinely useful for patients and providers. They also dig into findings from a study the Judi Health team recently presented at the Pharmacy Quality Alliance (PQA) annual meeting and explain why pharmacist support and clinical decision support, not just a lab report, make all the difference.Key TakeawaysPGx adds a piece to the puzzle; it's not a silver bullet. Pharmacogenomics looks at how inherited genetic differences affect the way a person processes or responds to medications. It narrows uncertainty and supports clinical judgment, but it doesn't replace it.Several forces are converging to make this the right moment. Testing costs have dropped, evidence-based guidelines from expert consortia are now widely adopted, and hundreds of FDA labels include pharmacogenomic information.The strongest use cases involve complexity and risk. Patients on multiple medications, those starting new therapies, and people who've had treatment failures or unexpected side effects often benefit most, especially across common drug classes like antidepressants, cardiovascular medications, and pain therapies.Human support drives engagement and trust. Rx Helix data showed that testing adoption was significantly higher among members who received clinician-led, pre-test telephone outreach.The future is proactive. With unified claims processing that combines pharmacy and medical data, leaders see a path toward PGx-enabled medication management, identifying patients before therapy begins to optimize treatment earlier in their journey.Related ContentHealth Benefits 101: The Importance of Clinical ProgramsAH073 - How Low Cost Alternative Programs Can & Should Work, with Jackie Lolos, PharmD, and Haleh Campbell, PharmDReplay – The Bridge to Better Healthcare: Uniting Medical and Pharmacy Services on One Platform to Achieve Value-Based CareAH060 - A New Approach to Colorectal Cancer (CRC) Screening, with GeneoscopyFor more information about this episode and its transcript, please visit Judi Health Insights.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.ResourcesCMS: CLFS & PAMA reporting and resourcesPrecision Oncology Therapeutics: Personalized cancer treatmentAnswers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic's patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Leyla Muedin, a registered dietitian nutritionist, discusses a UK Biobank analysis published in the Journal of Cachexia, “Sarcopenia and Muscle” (Nov 2025) linking continuous long-term statin use (e.g., Lipitor, Zocor, Crestor) to accelerated declines in grip strength and appendicular lean mass compared with never-users. Among 35,557 with follow-up data, grip strength declined by a mean 0.315 kg/year and appendicular lean mass by 0.057 kg/year in statin users; findings persisted after adjustment for age, sex, BMI, comorbidities, and a pharmacogenomic statin-response score. Leyla notes possible mechanisms (CoQ10/mevalonate pathway effects, mitochondrial dysfunction, apoptosis, calcium disruption, insulin resistance) and advises monitoring musculoskeletal health, supporting diet and regular physical activity, while not interpreting results as a reason to stop prescribing statins.

Broadcast from KSQD, Santa Cruz on 3-26-2026: li> Dr. Dawn announces a UCSF study recruiting participants for psilocybin therapy to help patients cope with chronic low back pain, requiring ages 25-70 with failed prior treatments. A caller preparing for bladder stone surgery asks about avoiding a repeat of severe post-anesthesia disorientation. Dr. Dawn recommends pharmacogenomic testing through 3x4 Genetics to identify slow acetylator status and other detoxification enzyme variants that can guide anesthesiologists toward better drug choices. A clinical trial found that 24 minutes of music with binaural beats—where slightly offset audio in each ear generates synchronized brainwaves—significantly reduced anxiety in medicated patients. Dr. Dawn encourages trying this accessible, low-risk intervention. Chronic noise exposure triggers oxidative stress, inflammation, and endothelial dysfunction, increasing cardiovascular disease risk. Data centers and server farms are emerging noise pollution sources, and Dr. Dawn recommends affordable noise-canceling headphones as a health investment. A Crohn's patient in Switzerland reports alarming neurological symptoms including speech arrest with preserved awareness and transient visual disturbances. He is having trouble finding any Functional Medicine trained physician and Dr. Dawn recommends emailing to info@ifm.org. Furthermore, Dr. Dawn suspects possible seizure activity from brain inflammation and recommends pursuing a sleep-deprived EEG and MRI through a neurology referral. MIT researchers discovered Interlectin-2, a protein that both strengthens the mucus barrier by cross-linking mucins and directly traps and kills pathogens like Salmonella and Shigella. Imbalanced levels may contribute to inflammatory bowel disease. Synthetic versions may be an effective treatment for inflammatory bowel disease. A 33-year-old man survived 48 hours without lungs after flu-triggered bacterial pneumonia caused ARDS and multiple organ failure. Surgeons removed both lungs treat septic shock while ECMO (extracorporeal oxygenation)sustained him until a successful double lung transplant. A meta-analysis of 43 studies involving millions of births found no evidence that acetaminophen use during pregnancy increases autism, ADHD, or intellectual disability risk, contradicting recent political claims. Green tea contains about 30% more L-theanine than black tea, with studies showing 200mg daily improves verbal fluency, sleep quality, and reduces anxiety. Decaffeinated green tea retains full theanine content. Pop star Robbie Williams developed scurvy while on GLP-1 weight loss drugs, highlighting that only 2 of 40+ major GLP-1 trials assessed vitamin intake. Dr. Dawn urges anyone on these medications to take a comprehensive multivitamin.

Menopause and perimenopause affect women greatly, yet they remain shrouded in stigma and misinformation. With that, how do we become equipped to embrace these stages of life without being overwhelmed with how to take care of ourselves whilst knowing our medical needs?In this episode of DNA Talks, Dr. Tracey Steady-Hardcastle sits down with Amy Alkon — award-winning writer, syndicated columnist, and author of Going Menopausal. With her trademark wit and rigorous approach to science, Amy unpacks the realities of menopause and perimenopause, exposing the vast gap between evidence-based research and the medical care women often receive.From battling misinformation in doctor's offices to uncovering the overlooked role of progesterone, Amy shares how women can reclaim agency over their health during one of life's most transformative stages. This episode is both a wake-up call and a toolkit for navigating hormonal transitions with clarity, courage, and humor.Dr. Tracey and Amy talk about Amy's self-journey into perimenopause and menopause with her gynecologist, leading her to dive into Here are the highlights of today's episode: 01:12 The Story Behind "Going Menopostal"10:50 One Concerning Thing and One Hopeful Thing20:44 Shifting Power from Institutions Towards the Individual?32:24 The Role of Pharmacogenomics and  Pharmacogenetics TestingIf you wish to learn more from Amy Alkon, check out the following links:Website: https://www.amyalkon.net/Instagram: https://www.instagram.com/amyalkonbookstagram______________________________________________________Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram: @dnatalkspodcastThe DNA Company Instagram: @thednacoThe DNA Company's Official Tiktok Account: @thednaco3Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

As 2026 gets underway we know that many take time around this new beginning to improve not only their physical, but also their mental health. With that in mind, we're rerunning an episode with Leanne Williams on the future of depression care. Leanne is an expert on clinical depression and is working on new ways to more precisely diagnose depression in order to develop more effective treatment. For anyone who has suffered from depression or knows someone who has, it's an episode that provides hope for what's on the horizon. We hope you'll take another listen and also share this episode with anyone who you think may benefit from the conversation. Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:01:43) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:03:31) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their timelines.(00:06:16) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:03) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:22) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging.(00:12:31) Cognitive Features of DepressionHow cognitive impairment plays a major role in certain depression biotypes.(00:14:11) Matching Treatments to BiotypesFinding appropriate treatments sooner using brain-based diagnostics.(00:15:38) Expanding Treatment OptionsPersonalizing therapies and improving treatment outcomes based on biotypes.(00:19:03) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:15) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:23:46) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:29) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:29:38) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Your Health University, Jamie sits down with Dr. Jimmie Williamson, Chief Behavioral Health Officer at Your Health, to break down why behavioral health belongs inside primary care—not outside it. Jimmie explains how telehealth lowered stigma, how mental health diagnoses (“F codes”) often correlate with frequent ER use, and why Your Health moved from intuition to data-driven referral models using tools like Power BI. They also map the full behavioral health ecosystem—from psych nurse practitioners to therapists to the psych pharmacist—and clarify when and how teams should refer patients for the right level of support. The takeaway is simple: earlier behavioral health intervention can improve lives, reduce hospital visits, and strengthen value-based care outcomes system-wide. www.YourHealth.Org

Dr Mark Hudson-Peacock is a Clinician turned serial entrepreneur, including being a trailblazer in the field of Pharmacogenomics - finding medicines that work better based on your individual genome. Pharmacogenomics was included in the NHS 10 Year Plan as a "big bet" to save the NHS. He is the founder/CEO of Mantara Health Ltd, responsible for launching the first commercially available Pharmacogenomics (PGx) test in the UK.

Episode 70 - Dr Mark Hudson-Peacock is a Consultant Dermatologist and founder and CEO of Mantara Health Ltd, responsible for launching the first commercially available Pharmacogenomics test in the UK. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

A large population study links trimethoprim-sulfamethoxazole to a rare yet nearly threefold higher risk of severe acute respiratory failure in healthy adolescents and young adults, reinforcing FDA warnings and the need for careful monitoring. Two extensive Cochrane reviews—including over 132 million people—confirm that HPV vaccination dramatically reduces cervical cancer, high-grade precancers, and anogenital warts without increasing serious adverse events. Kentucky's deadly pertussis surge highlights declining vaccine coverage and the critical role of maternal Tdap and timely childhood immunization to protect the most vulnerable infants.

Fluoropyrimidines such as 5-fluorouracil (5-FU) and capecitabine remain cornerstone chemotherapies in oncology. However, for patients with certain DPYD gene variants, these commonly used drugs can cause life-threatening toxicities due to impaired metabolism of the active compounds. In this episode of the Precision Medicine Pharmacist Podcast, host Melissa Smith, PharmD, explores how DPYD genotyping is transforming oncology care by helping clinicians identify patients at risk before toxicity occurs. Joined by Karen Merritt, an advocate for universal DPD testing and leader with the Test4DPD initiative, the discussion sheds light on how pharmacogenomics is shaping safer, more personalized cancer treatment. Together, they explore current evidence, new FDA updates, and implementation frameworks that empower pharmacists and oncology teams to prevent preventable harm through precision medicine.

In this podcast episode with Dr. Lili Milani, Head of the Estonian Biobank and Professor of Pharmacogenomics at the University of Tartu, we discuss how Estonia's national biobank has become a trusted platform where science, ethics, and personal agency meet. The Estonian Biobank began as a research initiative focused on the genetics of disease, but over time, its purpose has deepened and broadened. “The original goal was to understand how genes relate to diseases so we could improve care,” Milani explains. As more participants joined and the scope of available data expanded, the Biobank grew into a national tool for real, tangible benefits to people's personal lives. Tune in! 

This session focuses on various pharmacogenomics implementation models in oncology. Presenters discuss how pharmacogenomics was implemented at their respective institution, how each addressed unique barriers to implementation, and considerations for scalability, sustainability, and expansion of pharmacogenomics testing in oncology over the next 5+ years. CE for this episode expires two years after publication. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode dives into the future of pharmacy through the lens of pharmacogenomics (PGx). Dr. Melissa Smith speaks with Dr. Vanessa Lesneski about the steep decline in pharmacy school enrollment and how PGx could reignite interest in the profession. They explore how PGx has rapidly evolved from an elective to a core component of pharmacy education, the rise of certification and training pathways, and the expanding career opportunities in diverse care settings. The discussion also tackles critical questions around pharmacists' role in test interpretation, skepticism about PGx adoption, and what it will take for the field to move from niche to mainstream.

How can genetic insights change the way we treat cancer?In this episode of the PQI Podcast, Dr. Soni Tuteja, Director of Pharmacogenomics at Penn Medicine, shares how her team put pharmacogenomic testing into practice — and the impact it's had on patients. She highlights findings from her Journal of Clinical Oncology article on DPYD and UGT1A1 testing in GI cancers, showing how pre-treatment testing helped reduce toxicities, guide dose adjustments, and support safer therapy.Listeners will also hear about:Practical strategies to expand and sustain pharmacogenetic testing in real-world settingsHow pharmacists can lead patient counseling and program implementationThe role of NCODA's Positive Quality Interventions (PQIs), like DPYD testing before fluoropyrimidine treatment, in helping teams deliver safer, more personalized care

Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginHow do you tackle one of healthcare's biggest challenges from behind the pharmacy counter?That's the question at the heart

Scope of practice, Pharmacogenomics, Fellows of AANP, IPE, GAT,

Exploring the Complexities of Pharma Rebates with Ann Lewandowski In this Summer Short episode of Relentless Health Value, host Stacey Richter converses again with Ann Lewandowski about the intricate dynamics of pharmaceutical rebates, or as Lewandowski prefers, post-sale concessions.  The discussion delves into the nuances of these rebates, the impact they have on drug costs, and the hidden consequences for patients and plan sponsors.  They highlight articles and insights by Austin Chelko and Peter Hayes, touching on how rebates can disadvantage the pursuit of lower-cost generics and biosimilars, and can obstruct pharmacogenetic testing that ensures drug efficacy and safety.  The conversation also critiques the opacity of rebates, deemed trade secrets by pharma and PBM companies, and underscores the ethical and financial dilemmas posed by the current rebate-driven system. === LINKS ===

Episode: 2934 Reading the Molecules of Life.  Today, we read the molecules of life.

Send us a textSchedule an Rx AssessmentSubscribe to Master The MarginAccording to the Centers for Disease Control and Prevention (CDC), diabetes is about 17% more prevalent in rural areas than urban ones. With rural communities often facing barriers to accessing healthcare, including limited specialists and transportation. But what if there was a way to increase rural patient access to specialists? In this episode of The Bottom Line Pharmacy Podcast, Scotty Sykes, CPA, CFP® and Bonnie Bond, CPA talk with Leanna Schwend, PharmD, DCES, owner of  Yellowstone Pharmacy in Montana and founder of SugarBEAT for a powerful conversation on turning personal adversity into clinical innovation.After being diagnosed with type 1 diabetes just before graduating pharmacy school, Leanna's career trajectory transformed leading her to create one of the only certified diabetes education programs in a Montana retail pharmacy.Now, she's helping patients and other pharmacy owners bridge gaps in diabetes care, education, and revenue generation.This episode explores:The story behind Leanna's diagnosis and how it changed her missionBuilding and sustaining a certified diabetes education programCreating a digital support platform for patients, caregivers, and pre-diagnosis educationRevenue options: cash-based models vs. accredited servicesAnd more!More About Our Guest:Leanna Schwend is PharmD and independent pharmacy owner who is passionate about Health and Wellness beyond the prescription. Her expertise is in value-added clinical services and leadership with special interests in Diabetes Education, Pharmacogenomics, Nutrigenomics, the Endocannabinoid system, Mental Health, and so much more! Leanna graduated with a Doctor of Pharmacy of degree from the University of Montana Skaggs School of Pharmacy in 2011. She then stepped into the role of Pharmacist in Charge and manager of her family pharmacy, Yellowstone Pharmacy of Forsyth, and became CEO/Owner in 2022.She has successfully implemented an accredited diabetes education program through the American Association of Diabetes Care and Education Specialists, immunizations, medication synchronization, medication therapy management, and pharmacogenomics testing and consulting.She is a Diabetes Care and Education Specialist, holds a certification in Pharmacogenomics, and is a Montana Pharmacy Association Board of Directors.When Leanna turned 25, she was diagnosed with Type 1 diabetes. Through her own personal experiences and knowledge of living with diabetes, she is committed and devoted to educating individuals that they can do more than survive…they can THRIVE! In 2023, Leanna founded SugarBEAT Enterprise, in which she and her teammates aim to deliver a top-notch digital diabetes education solution that will empower individuals on their wellness journey.Learn more about Leanna and SugarBEAT:Leanna Schwend, PharmD, DCES LinkedInSugarBEAT WebsiteSugarBEAT FacebookSugarBEAT InstagramSugarBEAT LinkedInMore resources on this topic:Podcast - Driving Independent Pharmacy Profitability in 2025

This episode of the Astonishing Healthcare podcast is all about Pharmacogenomics (PGx), a critical component of precision medicine that ensures the medications prescribed to patients align with their genetic makeup.. To explain everything from what PGx is and barriers to broader adoption to the future state of integrated care, Burns Blaxall, PhD (Senior Vice President of Precision Medicine at Aranscia), and Caitlin Munro, PharmD (Sr. Clinical Programs Manager at Capital Rx), joined Justin Venneri in the studio.Burns and Caitlin discuss the growth of biomarkers on drug labels and use cases where PGx has been most helpful to date (e.g., behavioral health), the cost of testing, lack of insurance coverage and appropriate clinical guidelines, and the general level of physician awareness. They also dive into ongoing efforts to overcome the common barriers to using PGx and how Capital Rx is approaching the opportunity - leveraging Judi® - to bring PGx to employer plan sponsors and others who would like to offer plan members this option as part of the health benefits program. They also highlight the important role pharmacists can play on care teams and in the delivery of specialized care and acknowledge that regulation and legal action will help drive change and improve greater accessibility and usage of PGx tools, which, based on some of the stories shared, can transform the patient experiences and improve health outcomes.Related Content & Reference MaterialsValidation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug–Gene, Drug–Drug–Gene, and Drug–Gene–Gene Interaction Risks in a Large Patient PopulationAH005 - Star Ratings, MTM, & CMS Translation Requirements with Jay Tran, PharmDAH035 - Pharmacy Benefits 101: Clinical Programs, with Bonnie Hui-Callahan, PharmDAH006 - Pharmacy Benefits 101: Clinical Care Teams, with Amy Stockton, PharmDFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

Ever thought about why medications work differently for different people? In this episode of Absolute Gene-ius, we explore the exciting field of pharmacogenomics with Wendy Wang, pharmacogenetic laboratory supervisor at Children's Mercy Hospital in Kansas City. Wendy shares how genetics can influence drug metabolism, offering a glimpse into how precision medicine can revolutionize healthcare by tailoring treatments based on an individual's unique genetic makeup.At the heart of Wendy's research is CYP2D6, a cytochrome P450 enzyme responsible for metabolizing around 20% of all prescribed medications. She explains how her lab uses digital PCR to analyze copy number variations (CNV), offering a reliable and precise method to predict drug metabolism. Wendy dives into the complexities of structural variants, the role of digital PCR in enhancing assay efficiency, and why pharmacogenomics is a critical piece of the precision medicine puzzle. Her use of delightful metaphors—like comparing genetic testing to ladling soup—makes complex science both relatable and engaging.In the Career Corner, Wendy opens up about her winding path to molecular biology, which included studying classical antiquity and nearly pursuing a career in history. She emphasizes the importance of resilience in research, embracing failure as a learning opportunity, and encourages budding scientists to reach out to mentors and explore diverse interests. Plus, hear about her most embarrassing lab mishap (hint: it involves a fire alarm) and the proud moment of publishing her first, first-author paper.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Have you ever heard of pharmacogenomics? If you haven't - then you're in the right place! Pharmacogenomics talks about how our specific genes respond differently to medications that are provided to us.Join us today as our host, Dr. Lara Varden, introduces our Program Director Dr. Gabby Gutierrez on the podcast as they talk about the world of pharmacogenomics and how important it is to take this into consideration when it comes to maintaining your health. From sharing their own personal stories, to discussing the dangers of oversupplementation, this episode is sure to equip you in responding to your health before you experience any detrimental direct effects to your body.▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Inspiring Motivational Background by Stock-Waveshttps://www.stock-waves.com/https://protunes.net/Video Link:  https://www.youtube.com/watch?v=pbwVDTn-I0o&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG&index=5▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Music: Peaceful Corporate by Stock-Waveshttps://protunes.net/Video Link:  https://www.youtube.com/watch?v=I34bTKW8ud0&list=PLQtpqy3zeTGB7V5lkhkfBVaiZyrysv_fG▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

Want to break into pharmacogenomics and precision medicine? In this episode, I sit down with Dr. Josiah Allen, a precision medicine pharmacist with nearly 20 years of experience in genomics, psychiatry, and clinical research. We explore how pharmacogenomics is revolutionizing patient care, prescribing, and the role of pharmacists in the future of medicine. We cover: • How Josiah transitioned from industry to clinical practice in pharmacogenomics • The multidisciplinary approach to precision medicine at St. Elizabeth Healthcare • Why pharmacists are the ideal leaders in pharmacogenomics • The future of personalized medicine and emerging fields beyond PGx • How to successfully implement pharmacogenomics in a healthcare setting • The importance of patient empowerment, education, and shared decision-making If you're a pharmacist looking to future-proof your career and expand into precision medicine, this episode is a must-listen! Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Dr Josiah Allen [https://www.linkedin.com/in/allenjosiah] on LinkedIn About me:

This podcast will highlight opportunities for pharmacogenomic testing in solid organ transplant. The speakers will discuss their experiences and challenges with utilizing pharmacogenomic testing in this patient population.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, I have a chat with Kristine Ashcraft and Burns Blaxall about how precision-based prescribing is an essential tool for every pharmacist to adopt with urgency—we talk about: • Pharmacogenomics is a simple way to improve patient outcomes – If you think pharmacogenomics (PGx) is too complex? It's actually just another tool to help you do what you already do—optimize medications for better patient outcomes. Dr. Burns Blaxall breaks it down in a way that makes sense for everyday pharmacy practice. • Real-World proof: better outcomes, fewer medication failures – Studies show that PGx can reduce adverse drug events by 30% and prevent unnecessary ER visits and hospitalizations. If you've ever wished for a way to make sure a medication works before a patient even takes the first dose, this is it. • Making PGx work in your practice (don't let perfection be the enemy of the good) – The biggest roadblocks to using PGx? Lack of awareness, integration challenges, and concerns about reimbursement. But here's the good news—pharmacists don't have to wait for a perfect system to start making an impact. Small steps can lead to big results. • Strengthening your role as a healthcare provider – PGx is a powerful way to elevate your role in patient care and get recognized as a key decision-maker in medication management. Building strong relationships with physicians and demonstrating your value in clinical decisions can open new doors for your career. • Success Stories that show PGx in action – Imagine stopping a patient from undergoing an unnecessary, high-risk procedure—just by using PGx testing. That's exactly what happened in one case shared in this episode. If you've ever felt stuck in the cycle of dispensing and reacting to medication failures, PGx offers a proactive way to make a real difference. Join the ElevateRx Pharmacogenomics Summit to learn how to bring Pharmacogenomics to your practice - https://elevaterx.live/ Follow Kristine Ashcraft on LinkedIn - https://www.linkedin.com/in/kristineashcraft/ Follow Burns Blaxall on LinkedIn - https://www.linkedin.com/in/burnsblaxall/ About me:

The Future of Pharmacogenomics, State Rep Cook, & Super Culture | TWIRx  Howard McLeod, PharmD Katrina Azer About the ElevateRx Event - Pharmacogenomics Virtual Summit April 12, 2025 12pm -6pm ET About the ElevateRx Event: This event is for you if you want to: bring innovation and fresh ideas to your practice elevate your career with new skills and expertise learn how precision prescribing reduces adverse events and improves patient outcomes learn step-by-step how top pharmacogenomics pharmacists are successfully implementing PGx across various settings This event is open to pharmacists worldwide, providing practical PGx implementation strategies applicable across diverse healthcare settings. Bud Cook 50th Legislative District Pennsylvania House of Representatives GO BIG & COME HOME!! Representative Cook recently spoke at the Washington County commissioners monthly meeting about his newest initiative – “Come Home…GO BIG!” The initiative highlights Southwestern Pennsylvania, which consists of Washington, Fayette, Greene, Westmoreland and Allegheny counties, as the best place in the Commonwealth to live and work. “I stood before the commissioners and asked for a committed partnership from them in pursuing this idea,” said Cook. “I want to publicly thank them for the opportunity to present Come Home…GO BIG! I look forward to potentially working with them in the months to come.” - said Rep Cook In May 2021, Cook started to ask the public “Why Not Here?” As many people had the opportunity to work from anywhere during the pandemic, he questioned why people wouldn't want to live and work in one of the tightest-knit communities in the Commonwealth. Thus, began his focus to make Southwestern Pennsylvania a home for many and a tourist destination for others. Chris Cornelison, RPh Author & CEO SolutionsRx Creator of Super Culture™ Framework In Super Culture™, Chris Cornelison outlines five steps to transform workplaces into thriving environments where employees feel energized and appreciated. Drawing from his experience, he emphasizes the importance of building a Super Culture™, retaining talent, fostering collaboration, and improving results.

Get your Deep Dive Genetic Analysis with Dr. Panzner's team! Go here and use BSFREE as your discount code for $150 off! ----Dr. Tyler Panzner is a Ph.D. scientist with a deep background in pharmacology, cancer, neuroscience, and inflammation research. His passion for how different substances affect the body has been lifelong, but about seven years ago, he found his true calling in genetics and personalized medicine. Since then, he's been on a mission to create personalized vitamin, supplement, and lifestyle protocols tailored to each individual's unique biology.His approach is all about understanding what your cells truly need and uncovering which vitamins, supplements, or foods might not be a good match for your genetic makeup. He firmly believes that by aligning your habits with your genes, not only can you feel your best every day, but you can also lower your risk for chronic diseases in the long run. His practice focuses on genetically optimizing health, helping people unlock their body's full potential to truly thrive.Dr. Panzner sees a massive lack in supplement education across all sectors of healthcare, which shows up as unnecessary suffering as people feel worse due to the wrong supplement recommendations. He is driven to educate both practitioners for their practice and consumers in the supplement aisle of the store so they can make more informed decisions regarding their or their patient's supplementation strategies.Are there any specific questions/talking points you would like to include?: Lack of supplement pharmacology education, issues with the genetics space, cell signaling model of health, (hyper) personalized medicineLinks: https://www.drtylerpanzner.com/https://www.instagram.com/drtylerpanzner/https://www.facebook.com/dr.tylerpanznerhttps://www.linkedin.com/in/tyler-panznerhttps://www.youtube.com/channel/UC38rM0QfXxr5V3Bn4D0n9jghttps://www.tiktok.com/@drtylerpanznerOur Advice!Everything in this podcast is for educational purposes only. It does not constitute the practice of medicine and we are not providing medical advice. No Physician-patient relationship is formed and anything discussed in this podcast does not represent the views of our employers. The Fine Print!All opinions expressed by the hosts or  guests in this episode are solely their opinion and are not to be used as specific medical advice.  The hosts,  May and Tim Hindmarsh MD, BS Free MD LLC, or any affiliates thereof are not under any obligation to update or correct any information provided in this episode. The guest's statements and opinions are subject to change without notice.Thanks for joining us! You are the reason we are here.  If you have questions, reach out to us at doc@bsfreemd.com or find Tim and I on Facebook and IG.Please check out our every growing website as well at  bsfreemd.com (no www) GET SOCIAL WITH US!We're everywhere here: @bsfreemd  

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

In this episode: • A Goal Setting Framework for Pharmacists - learn how a structured approach to goal-setting helped me become an internationally recognized pharmacy writer and Pharmacogenomics Academy founder. • Discover why using a physical diary proves more effective than phone apps for goal tracking, eliminating digital distractions and enhancing focus. • 5-Category Goal System - Master a comprehensive goal-setting approach that  ensures balanced personal and professional development. • Quarterly Goal Breakdown Strategy - transform large objectives into manageable quarterly targets, perfect for implementing new pharmacy services like Pharmacogenomics testing or clinical programs. • Weekly and Daily Accountability System - Implement effective progress tracking through weekly reviews and daily morning manifestos, ensuring consistent goal alignment and achievement. Resources: • Download the Goal Setting Toolkit here: https://pharmxcel.kit.com/goal-setting • Subscribe to my YouTube channel and watch the episode here: https://www.youtube.com/@katrinaazer • Stay in the know about the future of pharmacy! Sign up for exclusive updates on ElevateRx, a must-attend to elevate patient care in 2025. Join the list here: https://elevaterx.kit.com/ • Book - Atomic Habits by James Clear

This Week in Pharmacy – December 13, 2024 Digital Health & Community Pharmacy: Best Buy Health's Three-Pronged Strategy | TWIRx  Join us for another exciting episode of This Week in Pharmacy (TWIRx) with host Todd Eury, featuring insightful discussions on the latest trends shaping pharmacy and healthcare. Special Guests: Brian Urban – Director of Strategy at Best Buy Health Ashton S. Maaraba, J.D. – President of Digital Health, iCare+ Topics Discussed: The Future of Digital Health & Community Pharmacy Best Buy Health's Three-Pronged Strategy: Consumer Health Products: Empowering healthier lifestyles through innovative devices. Emergency Response Services: Device-based solutions for active aging adults, ensuring safety and independence. Virtual Care Offerings: Connecting patients and physicians for seamless healthcare experiences. Ashton S. Maaraba shares insights on digital transformation in pharmacy, the integration of health tech, and how iCare+ is redefining patient engagement and care delivery. TWIRx News with Special Co-Host Dr. Ryan Paul Legislative Updates: U.S. Senators and State Representatives propose a bill to ban joint ownership of PBMs and pharmacies. What does this mean for the pharmacy landscape? Todd and Dr. Ryan Paul discuss the implications and potential impact on healthcare access and pricing. Pharmacogenomics in Specialty Pharmacy: Exploring the rise of pharmacogenomics and how it is reshaping personalized medicine. Opportunities for independent community pharmacies to offer cash-based pharmacogenomics services as a new revenue stream. Sponsors: IPC (Independent Pharmacy Cooperative): Empowering independent pharmacies with solutions to enhance profitability and patient care. Happier at Home: Supporting pharmacists in delivering home-based healthcare services for seniors and disabled individuals. Call to Action: Subscribe to This Week in Pharmacy on your favorite podcast platform and leave us a review! Follow us on social media for updates, behind-the-scenes content, and more industry insights. Learn more about Best Buy Health's innovative approach to digital health and iCare+'s initiatives at their respective websites. Stay informed and inspired with This Week in Pharmacy! Follow the Pharmacy Podcast Network: Website: PharmacyPodcast.com Twitter: @PharmacyPodcast LinkedIn: Pharmacy Podcast Network #PharmacyPodcast #DigitalHealth #CommunityPharmacy #Pharmacogenomics #PBMReform

In this exciting episode of the Pediatric Pharmacist Review Podcast, we're diving into the fascinating world of pharmacogenomics and its transformative impact on pediatric care. Our special guest is Dr. Kelly E. Caudle, Pharm.D., Ph.D., FCCP, an Associate Member in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital. Dr. Caudle brings a wealth of expertise to the discussion, with over a decade of experience in pharmacogenomics implementation. As the Director of the NIH-funded Clinical Pharmacogenetics Implementation Consortium (CPIC), she oversees groundbreaking work in translating genetic test results into actionable prescribing decisions. With CPIC publishing 28 gene-based clinical guidelines covering 29 genes and over 150 drugs, Dr. Caudle's leadership is reshaping personalized medicine for children worldwide. Tune in as we explore how pharmacogenomics is enabling tailored treatments for pediatric patients, improving medication efficacy, and minimizing adverse effects. Dr. Caudle also shares insights into her work at St. Jude Children's Research Hospital and offers a glimpse into the future of personalized pediatric care. Key Takeaways: What pharmacogenomics is and why it matters for pediatric medicine. How CPIC guidelines are helping clinicians make data-driven prescribing decisions. The role of genetic testing in improving medication safety and outcomes for children. Dr. Caudle's journey in leading pharmacogenomics research and clinical implementation. Guest Bio: Dr. Kelly E. Caudle is a leading expert in pharmacogenomics, with over 100 publications and abstracts to her name. Her work has advanced the clinical implementation of pharmacogenetics at St. Jude Children's Research Hospital and beyond. As a passionate researcher and educator, she has inspired countless professionals through her national and international presentations.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success.  After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.   Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director.  Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems.   Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University.  As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191